Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence

Daniel J. Caruso, Adrienne J.K. Carmack, Vinata B Lokeshwar, Robert C. Duncan, Mark S. Soloway, Balakrishna L Lokeshwar

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Purpose: Lack of reliable biomarkers limits accurate prediction of prostate-specific antigen biochemical recurrence (disease progression) in prostate cancer. The two inflammatory chemokines, osteopontin and interleukin-8 (IL-8), are associated with tumor angiogenesis and metastasis. We investigated whether osteopontin and IL-8 expression in prostate cancer correlates with disease progression. Experimental Design: Archival prostatectomy specimens (n = 103) were obtained from patients with minimum 72-month follow-up. Osteopontin and IL-8 expression was evaluated by immunohistochemistry and graded for intensity and the area. Association of osteopontin and IL-8 staining with biochemical recurrence was evaluated by univariate and multivariate models. Results: In tumor cells, osteopontin and IL-8 staining was higher in the recurred group (203.2 ± 78.4; 181.1 ± 89.3) than in the nonrecurred group (122.7 ± 76.6; 96.4 ± 85.6; P < 0.001). Higher osteopontin and IL-8 staining was also observed in benign areas adjacent to tumor in the recurred group, than in nonrecurred group. In univariate analysis, except age, all preoperative and postoperative variables and osteopontin and IL-8 staining scores were significantly associated with biochemical recurrence (P < 0.05). In multivariate analysis, margin status and osteopontin staining independently associated with biochemical recurrence within 72 months. Osteopontin, either alone or with IL-8 and seminal vesicle invasion, was a significant variable in predicting biochemical recurrence within 24 months. Osteopontin and IL-8 staining predicted recurrence with high sensitivity (75.5%; 73.6%) and specificity (76%; 70.6%). Conclusion: In prostatectomy specimens, osteopontin expression is independently associated with biochemical recurrence. Both osteopontin and IL-8 may be predictors of early disease progression.

Original languageEnglish (US)
Pages (from-to)4111-4118
Number of pages8
JournalClinical Cancer Research
Volume14
Issue number13
DOIs
StatePublished - Jul 1 2008

Fingerprint

Osteopontin
Interleukin-8
Prostatic Neoplasms
Recurrence
Staining and Labeling
Disease Progression
Prostatectomy
Neoplasms
Seminal Vesicles
Prostate-Specific Antigen
Chemokines
Research Design
Multivariate Analysis
Biomarkers
Immunohistochemistry

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence. / Caruso, Daniel J.; Carmack, Adrienne J.K.; Lokeshwar, Vinata B; Duncan, Robert C.; Soloway, Mark S.; Lokeshwar, Balakrishna L.

In: Clinical Cancer Research, Vol. 14, No. 13, 01.07.2008, p. 4111-4118.

Research output: Contribution to journalArticle

Caruso, Daniel J. ; Carmack, Adrienne J.K. ; Lokeshwar, Vinata B ; Duncan, Robert C. ; Soloway, Mark S. ; Lokeshwar, Balakrishna L. / Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 13. pp. 4111-4118.
@article{a7ff22c4ea2243b58e6d10afea3d8f4b,
title = "Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence",
abstract = "Purpose: Lack of reliable biomarkers limits accurate prediction of prostate-specific antigen biochemical recurrence (disease progression) in prostate cancer. The two inflammatory chemokines, osteopontin and interleukin-8 (IL-8), are associated with tumor angiogenesis and metastasis. We investigated whether osteopontin and IL-8 expression in prostate cancer correlates with disease progression. Experimental Design: Archival prostatectomy specimens (n = 103) were obtained from patients with minimum 72-month follow-up. Osteopontin and IL-8 expression was evaluated by immunohistochemistry and graded for intensity and the area. Association of osteopontin and IL-8 staining with biochemical recurrence was evaluated by univariate and multivariate models. Results: In tumor cells, osteopontin and IL-8 staining was higher in the recurred group (203.2 ± 78.4; 181.1 ± 89.3) than in the nonrecurred group (122.7 ± 76.6; 96.4 ± 85.6; P < 0.001). Higher osteopontin and IL-8 staining was also observed in benign areas adjacent to tumor in the recurred group, than in nonrecurred group. In univariate analysis, except age, all preoperative and postoperative variables and osteopontin and IL-8 staining scores were significantly associated with biochemical recurrence (P < 0.05). In multivariate analysis, margin status and osteopontin staining independently associated with biochemical recurrence within 72 months. Osteopontin, either alone or with IL-8 and seminal vesicle invasion, was a significant variable in predicting biochemical recurrence within 24 months. Osteopontin and IL-8 staining predicted recurrence with high sensitivity (75.5{\%}; 73.6{\%}) and specificity (76{\%}; 70.6{\%}). Conclusion: In prostatectomy specimens, osteopontin expression is independently associated with biochemical recurrence. Both osteopontin and IL-8 may be predictors of early disease progression.",
author = "Caruso, {Daniel J.} and Carmack, {Adrienne J.K.} and Lokeshwar, {Vinata B} and Duncan, {Robert C.} and Soloway, {Mark S.} and Lokeshwar, {Balakrishna L}",
year = "2008",
month = "7",
day = "1",
doi = "10.1158/1078-0432.CCR-08-0738",
language = "English (US)",
volume = "14",
pages = "4111--4118",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence

AU - Caruso, Daniel J.

AU - Carmack, Adrienne J.K.

AU - Lokeshwar, Vinata B

AU - Duncan, Robert C.

AU - Soloway, Mark S.

AU - Lokeshwar, Balakrishna L

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Purpose: Lack of reliable biomarkers limits accurate prediction of prostate-specific antigen biochemical recurrence (disease progression) in prostate cancer. The two inflammatory chemokines, osteopontin and interleukin-8 (IL-8), are associated with tumor angiogenesis and metastasis. We investigated whether osteopontin and IL-8 expression in prostate cancer correlates with disease progression. Experimental Design: Archival prostatectomy specimens (n = 103) were obtained from patients with minimum 72-month follow-up. Osteopontin and IL-8 expression was evaluated by immunohistochemistry and graded for intensity and the area. Association of osteopontin and IL-8 staining with biochemical recurrence was evaluated by univariate and multivariate models. Results: In tumor cells, osteopontin and IL-8 staining was higher in the recurred group (203.2 ± 78.4; 181.1 ± 89.3) than in the nonrecurred group (122.7 ± 76.6; 96.4 ± 85.6; P < 0.001). Higher osteopontin and IL-8 staining was also observed in benign areas adjacent to tumor in the recurred group, than in nonrecurred group. In univariate analysis, except age, all preoperative and postoperative variables and osteopontin and IL-8 staining scores were significantly associated with biochemical recurrence (P < 0.05). In multivariate analysis, margin status and osteopontin staining independently associated with biochemical recurrence within 72 months. Osteopontin, either alone or with IL-8 and seminal vesicle invasion, was a significant variable in predicting biochemical recurrence within 24 months. Osteopontin and IL-8 staining predicted recurrence with high sensitivity (75.5%; 73.6%) and specificity (76%; 70.6%). Conclusion: In prostatectomy specimens, osteopontin expression is independently associated with biochemical recurrence. Both osteopontin and IL-8 may be predictors of early disease progression.

AB - Purpose: Lack of reliable biomarkers limits accurate prediction of prostate-specific antigen biochemical recurrence (disease progression) in prostate cancer. The two inflammatory chemokines, osteopontin and interleukin-8 (IL-8), are associated with tumor angiogenesis and metastasis. We investigated whether osteopontin and IL-8 expression in prostate cancer correlates with disease progression. Experimental Design: Archival prostatectomy specimens (n = 103) were obtained from patients with minimum 72-month follow-up. Osteopontin and IL-8 expression was evaluated by immunohistochemistry and graded for intensity and the area. Association of osteopontin and IL-8 staining with biochemical recurrence was evaluated by univariate and multivariate models. Results: In tumor cells, osteopontin and IL-8 staining was higher in the recurred group (203.2 ± 78.4; 181.1 ± 89.3) than in the nonrecurred group (122.7 ± 76.6; 96.4 ± 85.6; P < 0.001). Higher osteopontin and IL-8 staining was also observed in benign areas adjacent to tumor in the recurred group, than in nonrecurred group. In univariate analysis, except age, all preoperative and postoperative variables and osteopontin and IL-8 staining scores were significantly associated with biochemical recurrence (P < 0.05). In multivariate analysis, margin status and osteopontin staining independently associated with biochemical recurrence within 72 months. Osteopontin, either alone or with IL-8 and seminal vesicle invasion, was a significant variable in predicting biochemical recurrence within 24 months. Osteopontin and IL-8 staining predicted recurrence with high sensitivity (75.5%; 73.6%) and specificity (76%; 70.6%). Conclusion: In prostatectomy specimens, osteopontin expression is independently associated with biochemical recurrence. Both osteopontin and IL-8 may be predictors of early disease progression.

UR - http://www.scopus.com/inward/record.url?scp=48249112605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48249112605&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-0738

DO - 10.1158/1078-0432.CCR-08-0738

M3 - Article

C2 - 18593988

AN - SCOPUS:48249112605

VL - 14

SP - 4111

EP - 4118

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 13

ER -